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Introduction
The NLRP12 related autoinflammatory disorder
(NLRP12-RD) is a rare autosomal dominant disease,
caused by mutations in the NLRP12 gene. Clinical mani-
festations are extremely heterogeneous.At present,only
few cases have been described.Patients occasionally
required treatment with steroids and NSAIDS for short
periods. Treatment with Anakinra induced an initial
good response,that appears to decrease over time.
Objectives
To describe clinical features and inflammatory response of
a cohort of patients carrying different NLRP12 variants,
some of which not yet described as being associated with
NLRP12-RD.
Methods
Twelve caucasian patients(6 males)carrying NLRP12 var-
iants were identified. Blood samples obtained from 9/12
NLRP12 patients and from 7 active Juvenile idiopathic
arthritis(JIA) patients were stimulated ex vivo with 1 mg/ml
of Zymosan for 22h.Whole blood RNA analysis was also
performed, using a human immune array(TaqMan®
Human Immune Array from Applied Biosystems), contain-
ing 92 genes typically involved in the immune response.
Results
The median age at symptoms onset was 11,4 months
(IQR 4, 6–35, 2) and the median of disease duration
was 6, 8 years(IQR 4,1–11). Sequencing of NLRP12 gene
in the 12 patients revealed 5 heterozygous mutations:
F402L(n=6), G448A(n=1), H304Y(n=1), R1030G(n=1)
and G39V(n=1). Two patients were homozygous for
NLRP12 variants: F402L and G39V. In 6/12 variants of
NLRP3 were also found: Q703K(n=4) and V198M(n=2).
All patients had symptoms consistent with a recurrent
inflammatory syndrome: 11/12 presented recurrent epi-
sodes of skin lesions, 11/12 arthralgia, 10/12 recurrent
fever episodes, 8/12 arthritis,10/12 headache, 11/12 fati-
gue, 5/12 conjunctivitis,7/12 recurrent abdominal pain
and lymphadenopathy,5/12 oral aphthosis, 4/12 thoracic
pain and 2/12 sensorineural deafness. During the attacks
5/12 patients showed increased acute phase reactants.In
5/12 patients anakinra was administered because of the
severity of phenotype and the persistence of elevated acute
phase reactants.In 2 of these 5 patients lack of efficacy led
withdrawal of anakinra and introduction of tocilizumab
with good response.In vitro cytokine release studies, per-
formed in 9 patients,showed that the production of IL-6
and TNF-a was significantly higher in patients carrying
the NLRP12 variants compared to patients with JIA (IL-
6:2841±1682 ng/ml and 1496±982.4 ng/ml versus 498.8
±338.7 ng/ml and 226.6±111.8 ng/ml respectively;
p=0.0002 and p=0.007)and even higher in homozygous
patients;no significant difference in IL-1b production was
found(2134 ± 1026 ng/ml versus 1527±930.3 ng/ml,
p=0.29).Whole blood RNA samples collected from 5
NLRP12 patients were compared to 6 whole blood RNA
samples collected from healthy controls comparable for
age.At basal level,we did not find significant differences in
the expression of 92 genes evaluated.
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Conclusion
Our data in vitro and in vivo suggest that these NLRP12
variants are pathogenic. The role played by the conco-
mitant presence of the NLRP3 variants remains to be
clarified,though an effect in modifying the disease phe-
notype cannot be excluded. Our data also confirm the
clinical and functional heterogeneity of NLRP12 related
disorder,a condition often misunderstood.Furthermore,
although the small number of patients treated,our data





1Division of Rheumatology, Department of Pediatric Medicine, IRCCS
Ospedale Pediatrico Bambino Gesù, Italy. 2Cytogenetics, IRCCS Ospedale
Pediatrico Bambino Gesù, Rome, Italy. 3Pediatric Rheumatology Unit,
Department of Rheumatology, Istituto Ortopedico G.Pini University of Milan,
Milan, Italy. 4Division of Pediatric, Santa Maria della Stella Hospital, Orvieto,
Italy.
Published: 17 September 2014
doi:10.1186/1546-0096-12-S1-P71
Cite this article as: Insalaco et al.: Clinical presentation and cytokine
production abnormalities in a cohort of patients carrying NLRP12 gene
variants. Pediatric Rheumatology 2014 12(Suppl 1):P71.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Insalaco et al. Pediatric Rheumatology 2014, 12(Suppl 1):P71
http://www.ped-rheum.com/content/12/S1/P71
Page 2 of 2
